Therefore, MDM2 is a therapeutic target for TP53 wild-type (WT) AML, and small molecule antagonists of MDM2, called nutlins, have been investigated in clinical trials for AML and myeloproliferative neoplasms (MPN) [30, 31]. This evidence concerns the gene MDM2 and acute myeloid leukemia.